[go: up one dir, main page]

CL2009000029A1 - Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras. - Google Patents

Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras.

Info

Publication number
CL2009000029A1
CL2009000029A1 CL2009000029A CL2009000029A CL2009000029A1 CL 2009000029 A1 CL2009000029 A1 CL 2009000029A1 CL 2009000029 A CL2009000029 A CL 2009000029A CL 2009000029 A CL2009000029 A CL 2009000029A CL 2009000029 A1 CL2009000029 A1 CL 2009000029A1
Authority
CL
Chile
Prior art keywords
treatment
alk
pharmaceutical composition
osteoporosis
arthritis
Prior art date
Application number
CL2009000029A
Other languages
English (en)
Inventor
Catherine Leblanc
Maude Nadine Pierrette Pipet
Peter Hunt
Claire Adcock
Urs Baettig
Katrin Spiegel
Rob Pulz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2009000029A1 publication Critical patent/CL2009000029A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)

Abstract

Compuestos derivados de piridina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la hipertensión pulmonar, fibrosis pulmonar y hepática, enfermedad renal, enfermedades articulares, Enfermedad de Alzheimer, artereosclerosis, entre otras.
CL2009000029A 2008-01-11 2009-01-09 Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras. CL2009000029A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08150187 2008-01-11
EP08168207 2008-11-03

Publications (1)

Publication Number Publication Date
CL2009000029A1 true CL2009000029A1 (es) 2009-07-24

Family

ID=40689319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000029A CL2009000029A1 (es) 2008-01-11 2009-01-09 Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras.

Country Status (22)

Country Link
US (1) US8343966B2 (es)
EP (1) EP2242742B1 (es)
JP (1) JP5566909B2 (es)
KR (1) KR20100101138A (es)
CN (1) CN101918362B (es)
AR (1) AR070519A1 (es)
AU (1) AU2009203681B2 (es)
BR (1) BRPI0907611A2 (es)
CA (1) CA2711803A1 (es)
CL (1) CL2009000029A1 (es)
CR (1) CR11490A (es)
EA (1) EA201001127A1 (es)
EC (1) ECSP10010336A (es)
ES (1) ES2562447T3 (es)
IL (1) IL206276A0 (es)
MA (1) MA31947B1 (es)
MX (1) MX2010007606A (es)
PE (1) PE20091316A1 (es)
TN (1) TN2010000255A1 (es)
TW (1) TW200938536A (es)
WO (1) WO2009087212A2 (es)
ZA (1) ZA201003929B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
DK2432767T3 (da) * 2009-05-19 2013-09-30 Dow Agrosciences Llc Forbindelser og fremgangsmåder til at kontrollere svampe
AU2011276193B2 (en) * 2010-07-05 2015-01-22 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2016009135A (es) 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MA45244A (fr) 2016-06-13 2019-04-17 Cancer Research Tech Ltd Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
WO2018213185A1 (en) * 2017-05-17 2018-11-22 Drexel University Rela inhibitors for biofilm disruption
AU2018388406B2 (en) 2017-12-22 2023-07-06 HiberCell Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN112243374A (zh) 2018-01-29 2021-01-19 卡普勒斯疗法有限责任公司 包括6元中心环的srebp抑制剂
CN116096719B (zh) 2020-07-15 2025-09-30 奇斯药制品公司 作为alk5抑制剂的哒嗪基氨基衍生物
KR20230041003A (ko) 2020-07-15 2023-03-23 키에시 파르마슈티시 엣스. 피. 에이. Alk5 억제제로서 피리도 옥사진 아미노 유도체
US20240116947A1 (en) 2020-07-15 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CN112707924A (zh) * 2020-12-26 2021-04-27 蚌埠中实化学技术有限公司 一种4-胺甲基苯硼酸盐酸盐的合成方法
AU2022351219A1 (en) 2021-09-21 2024-05-02 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
KR102556500B1 (ko) * 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물
EP4444429A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
EP4514802A1 (en) 2022-04-27 2025-03-05 Chiesi Farmaceutici S.p.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909529A (en) 1956-07-19 1959-10-20 Merck Ag E Process for preparing 3, 4-dihydro-1, 2-pyrano-(3, 4-c)-pyridone-(6)
BE789099A (fr) 1971-09-22 1973-03-21 Boehringer Sohn Ingelheim Nouveaux derives de la pyridine et procede pour les fabriquer
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
WO2007124544A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors - 1
JP2009535307A (ja) 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
WO2007124545A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors - 2
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
NZ581397A (en) 2007-04-27 2012-02-24 Astrazeneca Ab Pyrimidine compounds for the inhibition of Eph receptors and for the treatment of cancer
JP5456681B2 (ja) * 2007-10-17 2014-04-02 ノバルティス アーゲー ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体

Also Published As

Publication number Publication date
US20090215776A1 (en) 2009-08-27
PE20091316A1 (es) 2009-09-24
ECSP10010336A (es) 2010-08-31
JP5566909B2 (ja) 2014-08-06
MA31947B1 (fr) 2010-12-01
WO2009087212A3 (en) 2009-09-24
IL206276A0 (en) 2010-12-30
MX2010007606A (es) 2010-08-23
US8343966B2 (en) 2013-01-01
ES2562447T3 (es) 2016-03-04
ZA201003929B (en) 2011-03-30
AU2009203681A1 (en) 2009-07-16
EP2242742A2 (en) 2010-10-27
CR11490A (es) 2010-08-11
EA201001127A1 (ru) 2011-02-28
KR20100101138A (ko) 2010-09-16
WO2009087212A2 (en) 2009-07-16
BRPI0907611A2 (pt) 2015-07-21
CN101918362A (zh) 2010-12-15
TN2010000255A1 (en) 2011-11-11
AR070519A1 (es) 2010-04-14
CN101918362B (zh) 2013-11-27
EP2242742B1 (en) 2015-12-02
CA2711803A1 (en) 2009-07-16
JP2011509277A (ja) 2011-03-24
TW200938536A (en) 2009-09-16
AU2009203681B2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CL2009000029A1 (es) Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras.
CL2009000028A1 (es) Compuestos heterocíclicos derivados de 1h-pirrolo[2,3-b]piridina y 7h-pirrolo[2,3-b]pirimidina sustituidos; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de condiciones óseas asociadas con la resorción de calcio, útiles en el tratamiento de la hipertensión pulmonar, artritis, entre otras.
CL2007001142A1 (es) Compuestos derivados de sulfona, antagonistas del receptor il-8; procedimiento de preparacion;compuestos intermediarios;composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva cronica, dermatitis, psoriasis, alzheimer, aterosclerosis, osteoporosis.
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
CL2007002043A1 (es) Compuestos derivados de pirimidinas sustituidos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, hipertension pulmonar, fibrosis pulmonar, fibro
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
WO2010109334A3 (en) Thienopyrimidinedione derivatives as trpa1 modulators
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2009118596A3 (en) Phthalimide derivatives as trpa1 modulators
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
WO2006102308A3 (en) Beta-lactamyl vasopressin v1b antagonists
UY29454A1 (es) Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
BRPI0807615A8 (pt) Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
WO2013040227A3 (en) Therapeutic compounds